Abstract 1863P
Background
A descriptive, cross-sectional, multicenter study was carried out among the nursing staff working in several departments caring for cancer patients (Carcinology Sousse, Monastir, Sfax, Institut Salah Azaiez and Ariana).
Methods
The instrument used to measure CE was the "Professional quality of life" (PRO-QOL version5), which is composed of 3 subscales: 10 items to measure compassion satisfaction (SC), 10 items to measure professional exhaustion (PE) and 10 items to measure secondary traumatic stress (STS).
Results
A total of 120 health personnel responded to the questionnaire. The average age of the participants was 36.13±8.06 with a clear female predominance (sex ratio=0.29). Most respondents were physicians (55.9%). The mean CS score was 33.57±6.24, which is consistent with an average level of CS. However, 13.3% of the staff had a high SC score. The mean PE score was 29.88±5.12, which corresponds to an average level of PE. Only 10.9% had a low PE score. The mean STS score was 33.16±7.56, which corresponds to an average level of STS. However, 17.5% had a high STS score.
Conclusions
Compassion fatigue can lead to real burnout. Its prevention, detection and implementation of solutions to stem the process is essential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
1-Service of carcinological medicine CHU FarhatHached Sousse 2- Hospital hygiene service CHU FarhatHached Sousse 1-Service of carcinological medicine CHU FarhatHached Sousse 2- Hospital hygiene service CHU FarhatHached Sousse Service of carcinological medicine CHU FarhatHached Sousse and Hospital hygiene service CHU FarhatHached Sousse.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05